Cannabidiol and epilepsy: Rationale and therapeutic potential

Area of Science:

• Neuroscience
• Pharmacology
• Phytochemistry

Background:

• Epilepsy treatment remains challenging, with many patients experiencing poor quality of life and refractory seizures despite new antiepileptic drugs (AEDs).
• Phytocannabinoids, including cannabidiol (CBD), have a history of medicinal use for neurological disorders and are being investigated as alternative epilepsy therapies.
• CBD, a nonpsychoactive phytocannabinoid, exhibits anticonvulsant properties, though its precise mechanism of action requires further elucidation.

Purpose of the Study:

• To review the current preclinical and clinical evidence for cannabidiol (CBD) as a therapeutic agent for epilepsy.
• To assess the potential of CBD in managing refractory seizures and its side effect profile.
• To identify the need for further research to fully evaluate CBD's therapeutic potential in epilepsy.

Main Methods:

• Review of in vivo preclinical studies on CBD's anticonvulsant effects in acute and chronic seizure models.
• Analysis of clinical trial data investigating CBD's efficacy and safety in adult and pediatric epilepsy patients.
• Evaluation of existing literature on CBD's mechanism of action and comparison with other phytocannabinoids.

Main Results:

• Preclinical studies demonstrate significant anticonvulsant effects of CBD, primarily in acute seizure models, with limited data in chronic epilepsy and epileptogenesis models.
• Clinical evidence suggests CBD can manage refractory seizures in both adults and children, exhibiting a favorable side effect profile.
• Current clinical trials are limited in quality and number, yielding inconsistent results.

Conclusions:

• Cannabidiol (CBD) presents a promising therapeutic option for epilepsy, especially for refractory cases, supported by preclinical and emerging clinical data.
• While CBD shows a favorable side effect profile, further high-quality preclinical and clinical studies are essential to establish its efficacy, optimal use, and mechanisms in epilepsy management.
• The current data, though promising, is insufficient to definitively establish CBD as a standard epilepsy treatment, highlighting the need for more rigorous investigation.